Abstract
Aim: To evaluate adverse events in cancer patients with pre-existing sarcoidosis receiving immune checkpoint inhibitors (ICIs). Patients & methods: We retrospectively reviewed cancer patients with sarcoidosis who underwent treatment with ICI to determine frequency of sarcoidosis flares. Results: 32 patients with sarcoidosis received ICIs The median time to ICI initiation was 7 years (range: 1 month to 51 years). One patient (3%) with a 20-year remote history of sarcoidosis developed a clinically symptomatic exacerbation after three doses of atezolizumab, with hilar lymphadenopathy, subcutaneous nodules, arthritis and uveitis. Atezolizumab was discontinued and prednisone initiated. She had a fluctuating course with two additional flares. Conclusion: Frequency of flares in patients with a remote history of sarcoidosis who receive ICIs is low.
Original language | English (US) |
---|---|
Pages (from-to) | 465-475 |
Number of pages | 11 |
Journal | Immunotherapy |
Volume | 13 |
Issue number | 6 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- PD-1
- Sarcoidosis
- atezolizumab
- cancer immunotherapy
- immune checkpoint inhibitor
- immune-related adverse events
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology